Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

September 30, 2027

Conditions
Relapsed or Refractory B-cell Lymphoma
Interventions
DRUG

SR-GDP

Selinexor 40mg/d,po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg,po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.

Trial Locations (1)

200025

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER